People | April 04, 2024
Max CMD Abhay Soi is new president of NATHEALTH
New leadership team announced at NATHEALTH Annual General Meeting 2024
New leadership team announced at NATHEALTH Annual General Meeting 2024
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Application based on results from the TROPION-Breast01 Phase III trial
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
Lunaphore's flagship COMET technology is the only fully-automated, high-throughput, hyperplex platform with superior tissue profiling capabilities
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Subscribe To Our Newsletter & Stay Updated
